THIABENDAZOLE - Generic Drug Details

What are the generic sources for thiabendazole and what is the scope of patent protection?

Thiabendazole is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Summary for THIABENDAZOLE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	144
Clinical Trials:	1
DailyMed Link:	THIABENDAZOLE at DailyMed

Recent Clinical Trials for THIABENDAZOLE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Rigshospitalet, Denmark	Phase 2/Phase 3

See all THIABENDAZOLE clinical trials

Medical Subject Heading (MeSH) Categories for THIABENDAZOLE

Anthelmintics

US Patents and Regulatory Information for THIABENDAZOLE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	MINTEZOL	thiabendazole	TABLET, CHEWABLE;ORAL	016096-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Merck Sharp Dohme	MINTEZOL	thiabendazole	SUSPENSION;ORAL	016097-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Thiabendazole Market Dynamics and Financial Trajectory

Last updated: September 9, 2026

Thiabendazole is a mature, low-price benzimidazole with two separate commercial markets: human and veterinary antiparasitic use, and agricultural fungicide use. Its human pharmaceutical market has contracted sharply because ivermectin, albendazole and other alternatives are preferred in many indications. The agricultural market remains commercially relevant through post-harvest and plant-disease applications, but revenue is distributed across pesticide registrants, generic manufacturers and formulation suppliers rather than concentrated in a branded pharmaceutical franchise.

No reliable public source reports standalone global revenue for thiabendazole. Financial performance must therefore be assessed through product registrations, agricultural use, generic pricing, regulatory status and competitive substitution rather than company-reported molecule sales.

What is thiabendazole used for in pharmaceutical and agricultural markets?

Thiabendazole, also known as TBZ, is a benzimidazole compound with anthelmintic and fungicidal activity. Its commercial uses fall into three categories:

Market	Principal uses	Current commercial position
Human medicine	Strongyloidiasis, cutaneous larva migrans and selected intestinal helminth infections	Mature, largely generic and niche
Veterinary medicine	Treatment of gastrointestinal nematodes and related parasitic infections	Limited relative to newer veterinary anthelmintics
Agriculture	Post-harvest fungicide, seed treatment and control of fungal diseases	More durable than the human pharmaceutical market

The compound inhibits parasite tubulin function and interferes with microtubule formation. The same biological activity supports its fungicidal applications. Thiabendazole is identified by Chemical Abstracts Service number 148-79-8 and is listed in major chemical and pharmaceutical databases as an established benzimidazole active ingredient (National Center for Biotechnology Information, 2024).

What is the FDA status of thiabendazole and Mintezol?

The FDA approved thiabendazole under the Mintezol brand for treatment of selected helminth infections. The product was marketed in tablet and oral suspension forms. Mintezol is no longer a major branded human pharmaceutical product, and current U.S. access is primarily associated with generic or compounded availability rather than a large commercial brand.

The historical FDA label identified indications including strongyloidiasis, cutaneous larva migrans and trichinosis-related use. The label also described adverse effects such as nausea, vomiting, dizziness, headache and neurologic symptoms. These tolerability issues reduce its competitiveness against ivermectin and albendazole in many clinical settings (U.S. Food and Drug Administration, n.d.-a).

Is thiabendazole listed in the FDA Orange Book?

The Orange Book is primarily relevant to approved human drug products with active approval and listed patent or exclusivity information. Thiabendazole has no meaningful current Orange Book patent position comparable to recently launched small-molecule drugs. The former Mintezol franchise is an old product, and any original composition or product patents expired decades ago.

The practical consequence is that U.S. market entry is governed more by product approval, manufacturing capability, drug shortage conditions, reimbursement and clinical substitution than by patent exclusivity. A new applicant would face regulatory requirements for an abbreviated or full application, depending on the reference-product and product-specific circumstances, but would not generally face a live pioneer patent barrier.

When does thiabendazole lose exclusivity?

Thiabendazole lost meaningful market exclusivity many years ago. It was introduced in the 1960s, making any original compound patent estate commercially expired. The relevant exclusivity timeline is therefore historical:

Event	Approximate period	Commercial significance
Initial benzimidazole development and introduction	1960s	Originator-market formation
Mintezol human pharmaceutical commercialization	1960s onward	Branded antiparasitic use
Original compound and early product patent expiry	Decades ago	Generic entry became legally possible
Decline of branded human sales	Late 20th century onward	Substitution and limited demand
Current market	2020s	Generic, institutional and agricultural supply

No active patent portfolio appears to protect the core thiabendazole molecule in the United States, Europe or other major markets. Any current intellectual-property value would more likely arise from manufacturing processes, proprietary formulations, combination products, delivery systems or country-specific agricultural registrations. Those rights are narrower than a compound patent and generally do not recreate pharmaceutical exclusivity.

How strong is the patent estate for thiabendazole?

The patent estate is weak from an originator perspective and commercially mature.

Composition-of-matter patents

The composition-of-matter position has expired. Generic manufacturers can produce the active ingredient without infringing the original molecule patent, subject to local regulatory and manufacturing rules.

Formulation patents

Potential formulation claims could cover suspensions, stabilized liquids, veterinary dosage forms, agricultural concentrates, seed treatments or controlled-release products. These claims are technically possible but generally have limited strategic value unless they provide a material advantage in stability, residue control, bioavailability or application efficiency.

Method-of-use patents

Method-of-use patents could target a particular parasite, crop disease, dosing schedule or combination therapy. Such patents would need to satisfy novelty, non-obviousness and enablement standards. For an old active ingredient with extensive prior art, broad method claims would be difficult to sustain.

Manufacturing and process protection

Process know-how may have greater commercial relevance than molecule-level patents. Cost-efficient synthesis, impurity control, particle-size management and formulation stability can affect supplier competitiveness. Trade secrets can protect some of these advantages, but they do not prevent independent manufacture.

What generic entry risks exist for thiabendazole?

Generic entry risk is structurally high because the active ingredient is old, chemically defined and widely documented. The principal barriers are commercial rather than patent-based.

A new human pharmaceutical entrant would face:

1. Limited clinical demand relative to ivermectin and albendazole.
2. Low expected pricing because the product is mature.
3. Potential difficulty identifying a commercially attractive reference product.
4. Manufacturing and quality-control requirements for an older, low-volume drug.
5. Reimbursement uncertainty and inconsistent clinical use.

These conditions reduce the incentive for multiple U.S. manufacturers to maintain a dedicated product. The result can be a thin-supplier market even when legal entry is easy. In such markets, shortages or discontinuations can create temporary pricing increases without producing durable franchise value.

How does thiabendazole compare with ivermectin and albendazole?

Factor	Thiabendazole	Ivermectin	Albendazole
Human use	Narrower and declining	Broad antiparasitic use	Broad intestinal helminth use
Tolerability	Relatively unfavorable	Generally stronger clinical acceptance	Generally stronger clinical acceptance
Patent status	Long expired	Mature, largely generic	Mature, largely generic
Prescribing momentum	Low	High	High
Agricultural role	Significant fungicide use	Minimal	Minimal
Commercial outlook	Stable niche	Larger pharmaceutical market	Larger pharmaceutical market

Ivermectin and albendazole have stronger demand because of broader treatment guidelines and public-health procurement. The World Health Organization identifies ivermectin and albendazole as important medicines for several neglected tropical disease programs, while thiabendazole has a narrower role (World Health Organization, 2023).

This substitution is the central reason the human thiabendazole market has declined. The molecule remains clinically useful in selected cases, but clinical utility does not translate into high commercial volume when alternatives have better acceptance, broader indications or simpler dosing.

What is the agricultural market for thiabendazole?

Agriculture is the stronger long-term market for thiabendazole. It is used as a fungicide in post-harvest treatment and crop protection. Applications include control of storage fungi, molds and diseases affecting fruits, vegetables, potatoes, seeds and ornamental plants. Commercial products have historically included post-harvest formulations containing thiabendazole as the active ingredient.

The agricultural market is shaped by:

• Maximum residue limits established by national regulators and Codex Alimentarius.
• Crop-specific registrations.
• Export-market residue requirements.
• Resistance-management programs.
• Post-harvest loss reduction.
• Availability of alternative fungicides.

The U.S. Environmental Protection Agency has reviewed thiabendazole as a pesticide active ingredient and has maintained tolerance and registration information for crop uses. Agricultural registrations can remain commercially useful even when the human pharmaceutical franchise has little value (U.S. Environmental Protection Agency, 1999).

What companies compete in the thiabendazole market?

Competition is fragmented. The relevant participants include:

• Agricultural chemical companies that register and market formulated fungicides.
• Generic active-ingredient manufacturers in China, India and other production centers.
• Specialty pesticide distributors.
• Veterinary and pharmaceutical suppliers serving low-volume institutional demand.
• Contract manufacturers producing suspensions, concentrates and other finished forms.

The market is not dominated by a single global human pharmaceutical company. Competitive advantage is more likely to come from regulatory registrations, distribution access, formulation performance and manufacturing cost.

What is the financial trajectory for thiabendazole?

The financial trajectory is best described as declining human-pharmaceutical value with sustained agricultural utility.

Human pharmaceutical trajectory

Human sales likely peaked during the branded Mintezol era and then declined as patents expired, generic competition increased and physicians shifted toward ivermectin and albendazole. Current revenue is likely concentrated in low-volume generic, hospital, specialty pharmacy or compounding channels. Public company filings generally do not disclose thiabendazole revenue separately, which indicates that the product is not material to the financial statements of major diversified manufacturers.

The human market has limited capacity to support premium pricing, extensive clinical development or a standalone commercial organization.

Agricultural trajectory

Agricultural demand is more durable because thiabendazole provides a function that is distinct from its human antiparasitic use. Post-harvest treatment can reduce spoilage and preserve exportable crop inventory. Revenue is affected by crop production, food-safety requirements, resistance development and regulatory tolerances.

Agricultural sales are still exposed to substitution. Other fungicides, biological treatments and improved storage systems can displace thiabendazole. The active ingredient therefore has a stable but mature profile rather than a high-growth profile.

Revenue exposure by market

Revenue driver	Direction	Assessment
Human branded pharmaceutical sales	Down	Franchise largely obsolete
Human generic sales	Flat to low	Niche demand and limited pricing power
Veterinary use	Flat to down	Competition from newer anthelmintics
Agricultural fungicide use	Stable to moderate	Main source of continuing commercial value
Specialty formulations	Selective growth potential	Dependent on registration and performance
API supply	Competitive	Price pressure and fragmented production

What litigation and Paragraph IV activity affect thiabendazole?

No major current U.S. patent litigation or commercially significant Paragraph IV campaign is associated with the core thiabendazole molecule. The reason is straightforward: the principal patent rights expired long ago, and the remaining market is too small to support the litigation profile associated with a high-revenue branded drug.

Potential disputes would more likely concern:

• Agricultural registration and residue compliance.
• Trademark rights for legacy brands.
• Contract manufacturing.
• Product quality or contamination.
• Formulation-specific patents.
• Regulatory exclusivity for a new combination or delivery system.

A standard generic launch scenario would therefore involve regulatory approval and commercial validation rather than a patent settlement with an originator.

What biosimilar risk applies to thiabendazole?

Biosimilar risk is not applicable. Thiabendazole is a chemically synthesized small molecule, not a biologic. Competitive risk comes from conventional generic manufacturers, therapeutic substitutes and agricultural fungicide alternatives.

What is the geographic coverage of the thiabendazole market?

Thiabendazole has broad historical regulatory coverage, but active commercial intensity varies by country. Demand is strongest where:

• Export crops require post-harvest fungicide treatment.
• Food losses create economic value for storage protection.
• Veterinary or human antiparasitic access is limited.
• Agricultural registrations remain active.
• Generic API production is established.

The United States and Europe impose stricter residue, labeling and environmental requirements. Emerging markets may have stronger agricultural demand but more variable registration enforcement and pricing. Global suppliers must manage separate crop labels, residue limits, packaging requirements and local approval regimes.

Key Takeaways

• Thiabendazole is a mature benzimidazole with limited human pharmaceutical growth.
• The Mintezol franchise has no meaningful remaining compound-patent exclusivity.
• Current human demand is niche and faces substitution from ivermectin and albendazole.
• Agricultural fungicide use is the principal source of continuing commercial relevance.
• No major current Paragraph IV campaign, biosimilar threat or high-value patent litigation affects the molecule.
• Revenue is fragmented and not separately disclosed by most diversified companies.
• The strongest commercial assets are agricultural registrations, formulation know-how, distribution and low-cost manufacturing.
• Financial upside from the human pharmaceutical market is limited unless a company develops a differentiated formulation or secures a supply-constrained niche.

FAQs About Thiabendazole Market and Patent Outlook

Is thiabendazole still commercially available?

Yes. Availability depends on country, indication and product type. Agricultural formulations remain more commercially visible than human pharmaceutical products.

Is thiabendazole profitable for generic drug manufacturers?

It can support low-volume specialty sales, but its age, low pricing and narrow human demand make it unlikely to support a large standalone pharmaceutical business.

Does thiabendazole have active U.S. patents?

The original molecule patents expired decades ago. Any current protection would likely involve a narrow formulation, process, combination or agricultural registration rather than the active ingredient itself.

Why did doctors stop using thiabendazole as widely?

Ivermectin and albendazole generally offer broader clinical utility and stronger prescribing acceptance. Thiabendazole’s adverse-effect profile and narrower role reduced demand.

Can a new company launch a thiabendazole product without a patent license?

A company can generally avoid a license to expired compound patents, but it must satisfy applicable FDA, EPA, veterinary, environmental, manufacturing and labeling requirements.

References

1. National Center for Biotechnology Information. (2024). PubChem compound summary for thiabendazole. U.S. National Library of Medicine.
2. U.S. Environmental Protection Agency. (1999). Reregistration eligibility decision: Thiabendazole.
3. U.S. Food and Drug Administration. (n.d.-a). Mintezol prescribing information and historical drug labeling.
4. U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations.
5. World Health Organization. (2023). WHO model list of essential medicines, 23rd list. WHO.